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Background: Supraventricular tachycardia (SVT) in children can be successfully terminated using
catheter ablation techniques; however, chronic, true success may be less. Sensed tachycardia (ST)
is common following ablation and the differentiation from true arrhythmia recurrences can be
challenging.
Methods: Records of all patients 18 years who underwent successful ablation for simple forms of SVT
and followed-up for at least a year between 2002 and 2012 were reviewed. Patients with congenital heart
disease, atrial muscle tachycardia, and associated ventricular tachycardia were excluded. The diagnostic
utility of commonly performed tests was assessed.
Results: Among the 205 eligible subjects, 202 underwent successful ablation (98.5%), of who five were
lost to follow-up before 1 year. The early success rate (6 weeks postablation) and mid-term success rate
(1 year postablation) were high (97.5% and 87.4%, respectively) whereas the chronic success (5 years
postablation) was only 75%. Although true arrhythmia recurrence was significantly higher in the young
(mean 11.5 years vs 13.5 years, P = 0.03) and males (P = 0.02), the presence of diffuse, right-sided
fibers was the only independent predictor of true recurrence (odds ratio = 2.7, P = 0.03, 95% confidence
interval 1.1, 6.8). Significant ST was reported by 111 patients (56%). The 30-day ambulatory event monitor
had the highest sensitivity (71%) when compared to exercise test (19%) and electrocardiogram (24%) in
identifying true arrhythmia recurrence.
Conclusions: Acute and early success may not guarantee chronic ablation success. Postablation,
symptomatic patients can be most effectively evaluated using ambulatory event monitoring; however,
true recurrence may still be missed and requires closer monitoring. (PACE 2014; 37:1009–1016)
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Introduction
Supraventricular tachycardia (SVT) is the
most common symptomatic arrhythmia in child-
hood and can be a recurrent and persistent condi-
tion. The incidence of this condition is estimated
to be one in 100 for children of all ages and one in
200 to 250 for neonates.1,2 Most forms of reentrant
SVTs involve an accessory conduction pathway
that participates in initiation and propagation of
tachycardia and is amenable to ablation. While
medical therapy is effective in reducing frequency
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of episodes in some cases, ablation of the accessory
pathways (APs) in the electrophysiology (EP)
laboratory, using cryotherapy or radiofrequency
energies, remains the treatment of choice for
symptomatic older children.3–5 Several studies
have shown extremely high rates of acute success
with ablation (>96–98%).5,6 However, data are
limited on long-term recurrence rates of SVT, and
therefore true success, in this population.7
It is recognized that from 30% to 60% of pa-
tients continue to experience sensed tachycardia
(ST) in the postablation period.4,8 All episodes
of ST, however, do not indicate true arrhythmia
recurrence and may represent heightened sen-
sitivity to sinus tachycardia. These patients are
routinely evaluated by means of several clinical
tests including resting electrocardiogram (ECG),
exercise stress testing, and ambulatory event
monitoring (AEM). While these tests are useful
in the initial diagnosis of SVT, their diagnostic
yield in predicting arrhythmia recurrence in the
postablation period has not been studied.9–13
©2014 Wiley Periodicals, Inc.
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This study was designed to assess, first, the
incidence of ST in children who have undergone
successful SVT ablation and, second, to evaluate
the diagnostic utility of various clinical tests in
identifying true arrhythmia recurrence.
Methods
This was a retrospective study conducted at
The Children’s Hospital of Michigan. The study
was approved by the Institutional Review Board,
Wayne State University School of Medicine.
All patients up to 18 years of age who were
diagnosed with any form of SVT and subsequently
had undergone radiofrequency or cryocatheter
ablation in our EP laboratory between 2002 and
2012 were identified. Those patients who had
successful ablation andwere followed in our clinic
for a minimum duration of 1 year were included.
Patients with atrial muscle tachycardia, structural
congenital heart defects (CHD), those with associ-
ated ventricular tachycardia, and with a history of
a surgical maze procedure for SVT were excluded.
Also, to facilitate correlation of complaints with
results, only those patients who underwent
ablation for typical forms of reentrant SVT as the
primary tachycardia substrate were included.
All clinical, intracardiac electrophysiological
study (EPS), and follow-up data on the study
group were reviewed. This included demographic
data, type of SVT, findings during EPS, follow-up
data after the initial ablation including symptoms,
results of investigations for evaluation of ST, and
any documented episodes of recurrent SVT.
Ablation Procedure
All patients underwent established EPS under
the same protocol by two pediatric electrophysiol-
ogists. All procedures were performed under stan-
dard general anesthesia. A three-dimensional (3D)
mapping system (St. Jude Medical, Minneapolis,
MN, USA) was used to define anatomical and elec-
trical landmarks for all patients post mid-2007.
Standard programmed electrical stimulation (PES)
protocols were instituted to induce tachycardia
including risk stratification of each patient with
evaluation of refractory periods and inducibility
of arrhythmias. Once the arrhythmia substrate and
any APs were identified, radiofrequency ablation
(RFA) and/or cryoablations were performed
per protocol. All patients were observed for 60
minutes following apparently successful ablation.
This was followed by a full repeat PES with and
without isoproterenol to evaluate ability to rein-
duce any arrhythmia, as well as administration
of adenosine to confirm evidence of any residual
accessory orthodromic connections. All patients
were observed overnight and evaluated by means
of a standard 15-lead ECG to reconfirm a normal
QRS and echocardiogram/Doppler to evaluate
atrioventricular valve integrity and effusion.
Follow-Up after Ablation
All patients were advised to have a follow-up
visit at 1 week and between 4 weeks and 6 weeks
following ablation in our EP clinic, and then
routinely at 1 year. Subsequent follow-up was
advised as needed for any symptoms. At the first
postablation visit, all patients were evaluated
with a detailed history and standard 15-lead ECG.
An exercise stress test (ET) depending on the
patient’s ability to perform the test, as well as
history and ECG, were scheduled at the 4–6-week
visit. If patients complained of any ST during
any of the subsequent follow-up visits, they were
additionally evaluated by means of an ECG, AEM,
and/or ET as per clinician’s decision. If patients
presented to the Emergency Room with ST and
had documented arrhythmia recurrence, medical
management was initiated. A repeat EP procedure
was performed based on clinical presentation of
the patient.
Statistics
All data were reported as mean and standard
deviation for continuous variables and frequency
for categorical variables. For statistical analysis,
patients who presented with ST following the ini-
tial ablation were selected. Kaplan-Meier curves
were constructed to analyze survival free of true
recurrence following ablation. Patients with and
without a true recurrence were compared using
independent sample t-test, Mann-Whitney U test,
Fisher’s exact, or χ2 tests depending on the distri-
bution of the data. Mutivariate logistic regression
was performed using recurrence as dependent
variable and adjusted odds’ ratio with 95%
confidence interval was calculated. The results
of various diagnostic modalities done to evaluate
ST were analyzed. Sensitivity, specificity, and
diagnostic yield of each modality were calculated
in identifying true arrhythmia recurrence. All
statistical analyses were performed using SPSS
version 18.0 (IBM Corp., Armonk, NY, USA).
Results
During the 10-year study period, a total
of 515 patients underwent ablation procedures
in our EP lab. Of these, 197 patients met the
eligibility criteria for inclusion in this study. The
mean age at ablation was 12.7 ± 3.9 years and
the majority of the patients were males (N =
120, 61%). Patients were followed for a mean
duration of 71 ± 40 months (median 66 months).
Figure 1 illustrates the Kaplan-Meier curve for
freedom from arrhythmia recurrences. There was
no significant difference between the duration
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Figure 1. Kaplan-Meier curve for freedom from arrhythmia recurrences.
of follow-up among patients with and those
without recurrence. Patients with true arrhythmia
recurrence were significantly younger at the time
of initial ablation and were more likely to be
males (Table I). Figure 2 provides patient numbers
during follow-up separated by “success” category:
acute, early, mid-term, and chronic, as described
below.
Acute Success Rate
Following ablation, all patients were observed
for 60 minutes in the EP lab. Acute success
was defined as: (1) a normal QRS and no
visible preexcitation among those patients with
previous preexcitation, (2) inability to reinduce
arrhythmia in spite of repeat PESwith andwithout
isoproterenol infusion, (3) no evidence of residual
preexcitation following adenosine administration.
Three patients continued to have preexcitation
following ablation (acute success rate: 98.5%).
Early Success Rate
Early success rate was defined as freedom
from clinical arrhythmia recurrence at the time
of first follow-up visit at 4–6 weeks and was
achieved in 97.5% patients. Five patients (2.5%)
had clinical arrhythmia recurrence. None of
these patients had residual preexcitation or any
abnormal rhythm on resting ECG.
Mid-Term Success Rate
Mid-term success was defined as freedom
from arrhythmia recurrence at 1 year and was
87.4%. Of the 20 patients who had clinical recur-
rence between 6 weeks and 1 year, six (30%) had
residual preexcitation on their follow-up ECG and
one (5%) had persistent preexcitation during ET.
Chronic Success Rate
Chronic persistent success was defined as
freedom from clinical arrhythmia recurrence at 5
years postsuccessful ablation and was about 75%.
Fifty patients (25%) had a clinical arrhythmia
recurrence by 5 years, of who 25 (12.5%) had
recurrence after 1-year postablation. Of these 25
patients, six (24%) had residual preexcitation on
routine ECG and two had persistent preexcitation
during ET.
Arrhythmia Substrate in Patients with True
Arrhythmia Recurrence
During the initial ablation, RFA and/or cryo
were used depending on the location of the
APs. Cryoablation with or without RFA was
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Table I.
Comparison of Patients with and Without Clinical Arrhythmia Recurrence Following Successful Tachycardia Ablation (N =
197)
Recurrence No Recurrence P OR (95% CI)
(N = 50) (N = 147) Value Adjusted P†
Age at ablation (years) 11.7 ± 4.2 13.5 ± 3.4 0.003 NS
Gender (male) 34 (68%) 36 (24%) 0.001 NS
Type of tachycardia
Atrioventricular reciprocating tachycardia
Right-sided fibers 25 (50%) 48 (33%) 0.04
discrete AP‡ 12 (24%) 28 (19%) NS
diffuse nondiscrete AP 13 (26%) 20 (14%) 0.04 2.7 (1.1, 6.8), 0.03†
Left-sided AP 6 (12%) 51 (35%) 0.02 NS
Bilateral AP 4 (8%) 5 (3%) NS
Atrioventricular nodal tachycardia 13 (27%) 37 (25%) NS
Ectopic atrial tachycardia 2 (4%) 4 (3%) NS
Sinus node reentry tachycardia 0 (0%) 2 (1%) NS
Duration of follow-up (months)
Mean ± SD 79.8 ± 38.2 68.3 ± 41.3 NS
Median (interquartile range) 76 (50, 103) 61(40, 94)
†Multivariate logistic regression analysis. AP = accessory pathway; CI = confidence interval; OR = odds ratio; SD = standard deviation.
preferably used for atrioventricular node reentrant
tachycardia (AVNRT) and right anteroseptal fibers
to optimize avoidance of atrioventricular node
conduction damage. RFA alone was preferred
for left-sided fibers. Electroanatomic 3D mapping
was used for all patients post mid-2007. The
incidence of right-sided fibers was significantly
higher in patients with true recurrence (Table I).
On multivariate regression analysis, the presence
of APs in a right-sided diffuse distribution pattern
at initial ablation was the only independent risk
factor for recurrence. Forty-six patients underwent
repeat EP study for management of arrhythmia
recurrence. Twenty-one patients (46%) had a
residual arrhythmia substrate/AP location similar
to the initial EP ablation. Thirteen patients (28%)
had a new substrate/AP in a different location.
Eight patients (17%) were found to have AP in
a new location in addition to the residual AP from
initial ablation. Atrial flutter was induced in two
patients and no arrhythmia could be induced in
two patients (4%).
Evaluation of ST
Of the 197 patients, 111 patients (56%)
reported significant ST which was defined as re-
current, severe subjective sensation of palpitations
interfering with patient’s daily activities and/or
requiring emergency room visit over a 5-year
follow-up period after initial ablation (Table II).
These patients were evaluated with ECG, ET, and
AEM. Patients received ambulatory monitors typ-
ically based on age and potential for compliance.
Younger patients typically received “nonlooping”
monitors, as compliance with wearing a monitor
continuously is often less-than-optimal. The AEM
was the most sensitive and specific test with a
high negative predictive value (Fig. 3). ECG and
ETwere found to have limited utility in predicting
true arrhythmia recurrence.
Discussion
SVT is the most common arrhythmia in
childhood and typically is associated with ac-
cessory bypass pathways for propagation. The
destruction or modification of these pathways
using ablation therapy is a safe and effective
mode of treatment for older children. While
several authors have reported extremely high
acute success rates of eliminating the tachycardia
with ablation, the long-term prognosis for these
patients has not been adequately studied. Our
study aims to fill this gap by investigating the
long-term success rates in a growing pediatric
population following ablation for SVT. The results
of acute success rates following ablation were
comparable with previous studies, approaching
nearly 100%. However, over an average follow-
up duration of 6 years, more than half of the
patients reported repeated subjective sensations
of tachycardia. About one-third of these patients
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Persistent preexcitation after ablation (N=3) 
Loss to follow up before 1 year (N=5) 
Excluded 
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 4. Electrophysiology study 
Figure 2. Summary of study design and results. CHD = congenital heart disease; EP =
electrophysiology; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
had true documented recurrence of the SVT. These
results therefore indicate that acute success in
eliminating tachycardia may not always translate
into long term, true success. This is also the
first study that investigates the relative utility
of clinical testing in identifying true arrhythmia
recurrence among the patients presenting with
significant ST following ablation.
Some authors have previously reported
postablation outcomes. LaPage et al. studied 61
pediatric patients who underwent cryoablation for
AVNRT.3 About 15% patients had recurrent SVT
over 2 years. Our current report presents data on a
much larger group over a longer follow-up period
with a recurrence rate of 25%. Unlike the previous
study, our sample was not limited to AVNRT or
cryoablation. Chetaille et al. studied outcomes of
RFA in 83 patients with CHD over a mean follow-
up duration of 44 ± 35 months with a chronic
success rate of 59% of procedures.14 In our current
study, the follow-up durationwas 71± 40months,
the longest reported postablation interval in
pediatric population to date.We excluded patients
with CHD due to heterogeneity of this population
and the inherent differences in their conduction
system when compared to the children with struc-
turally normal heart.15 In this aspect, we believe
this report more accurately reflects true ablation
success in the real world of pediatric tachycardia
management, ablation, and growing children.
Our study shows that the location of the AP
was the only independent predictor of arrhythmia
recurrence a 5 years. Patients with diffuse
right-sided fibers at initial ablation were three
times more likely to have arrhythmia recurrence
compared to those with discrete fibers. In a
previous study, Buddhe et al. compared abla-
tion energy sources (RFA vs cryoablation) with
recurrences among 87 pediatric patients.5 The
overall recurrence rate was similar in two groups
(22% vs 20%, respectively) over 5 years, with
location as an important variable for recurrences.
That study showed a predominance of right-sided
fibers similar to our current study. Van Hare
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Table II.
Evaluation of Significant Sensed Tachycardia in Patients with and without Recurrence at 5 Years Postablation (N = 111)
Recurrence No Recurrence
(N = 50) (N = 61)
Electrocardiogram† 12/50 (24%) 4/61 (6%)
Exercise stress test‡ 5/26 (19%) 0/20 (0%)
Ambulatory event monitor 18/25 (72%) 0/38 (0%)
Looping recorder 10/14 (71%) 0/18 (0%)
Non looping recorder 8/10 (80%) 0/17 (0%)
ECAT/Implantable loop recorders 1/2 (50%) 0/0 (0%)
†Abnormal test defined as persistent preexcitation at rest, ‡abnormal test defined as persistent preexcitation and/or documented SVT
with exercise.
ECAT = extracardiac ambulatory telemetry.
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Figure 3. Diagnostic utility of tests performed to evaluate sensed tachycardia (N = 111).
et al. conducted a large prospective study of 2,761
pediatric patients to evaluate outcomes after SVT
ablation.6 The acute success rate for left-sided APs
(98%)was significantly higher than the right-sided
fibers (91%). The study however did not assess
long-term outcomes.
The reasons for increased recurrence with dif-
fuse right-sided fibers are purported to be associ-
ated with anatomy. Diffuse arrangements of fibers
are identified during mapping/ablation when the
ablation catheter crosses at least two “adjacent”
mapping regions (e.g., anterior/anteroseptal).16 Of
course, it is well known that these “regions” are
hypothetical and based more on fluorscopic/3D
mapping appearances than any actual anatomical
references. These diffuse fibers are characterized
histologically by wide AP branching and spatial
separation and may present with a clinical
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picture of multiple or broad-distribution con-
nections, hindering effective catheter mapping
and ablation.17,18 The associated folding of the
atrium over the ventricle, inherent anatomical
variability of the right-sided AV ring, AP physical
characteristics, and orientation relative to atrial
and ventricular myocardium may all contribute to
an inherent overlap among the sites, especially on
the right. In the previous era of surgical ablation,
an extensive valve annuloplasty was often per-
formed to ensureAP interruption.19 These patients
with diffuse connections in our study population,
therefore, may have had less optimal ablation
results than those with more discrete connections.
Our present study also shows that patients with
true recurrence are typically younger at the time
of ablation. The younger age of the patient and
nonlocalized distribution of the fibers as described
above may preclude more aggressive ablation in
order to reduce damage to the normal conduction
system. Therefore, this may account for a higher
recurrence rate in our study.
ST is common (30–60%) in the postablation
period.4,8 All episodes of ST, however, do not
indicate true SVT recurrence and may only rep-
resent heightened sensitivity to sinus tachycardia.
Among the few published studies, Mann et al.
interviewed 77 patients, 4 weeks after undergoing
ablation for SVT.8 Of these, 58% (N= 45) reported
ST but only 24% (8/32) were found to have
evidence of recurrent AP on repeat EP study
done after 3 months. Tomaske et al. followed
97 pediatric patients for 6 months after ablation.
Of these, only 6% had true recurrence.4 The
literature already has multiple “acute” success
studies and limited 4–6 months follow-up results.
Nevertheless, distinguishing true episodes of
recurrence from sensed sinus tachycardia remains
a common diagnostic challenge for the clinician.
While several tests are routinely employed to
identify “true” episodes, our study is one of the
first to look at the diagnostic utility of these
tests. Recently, AEMs have gained popularity
in the evaluation of palpitations in children.9,10
Park et al. studied 30 children who underwent
AEM for symptoms of palpitations and were
accurately diagnosed.11 In a previous study at
our institution, 202 symptomatic children were
evaluated with either 24-hour Holter monitor (N=
97) or telephone AEMs (N = 105). The study
showed that 30-day AEMs had a better correlation
of symptoms with arrhythmias (32% vs 5% for
Holter).9 Our present study also shows that AEMs
had the highest sensitivity and specificity in
identifying true SVT recurrence. However, up to
29% of events may still be missed with AEMs
in symptomatic patients. The possible reasons
could be patient noncompliance in following
instructions or difficulty in transmitting the data.
Newer devices, with patient-friendly capabilities
may have better sensitivity in detecting these
episodes and further studies are required to
evaluate their diagnostic utility.
The study has some limitations. This was
a retrospective study from a single institution.
Complaints of ST were evaluated without a
standardized protocol and based on clinical
judgment and therefore the results of testing were
nonuniform. Also the recurrence rates in patients
who were lost to follow-up cannot be estimated.
However, despite these limitations, the study
provides useful clinical information about the
long-term outcomes of ablation therapy of SVT in
children. Our large study sample and long follow-
up period allows for realistic estimation of acute
and long-term success rates in these patients. The
study also focuses on a very common clinical
problem of ST and hopes to provide some insight
into the utility of diagnostic testing.
Conclusions
Acute success following ablation in the EP
lab does not define chronic ablation success.
Subjective complaints of ST are common in
children; however, true recurrences occurred in
only one-fourth of patients and can be related
to the location of the AP. Although event
monitors are the most sensitive diagnostic tool
for predicting true recurrence, the diagnosis can
still be missed in a significant number of patients.
Longitudinal studies comparing different types of
event monitors are needed for most cost-effective
management of this common clinical problem.
Persistent clinical monitoring of children follow-
ing ablation is warranted.
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